Chronic obstructive pulmonary disease (COPD) is a chronic smoking-related lung disease associated with significant mortality and morbidity. It carries an enormous economic burden on the health care system. This results in a significant social impact on affected patients and their families. In this article, we review COPD in general, critical care management of patients presenting with acute exacerbation of COPD, and methods of prevention.
DEFINITIONS
COPD is a common, preventable, and treatable disease. It is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. 5 By far the most common cause of COPD is tobacco smoking, with a number of other influencing factors such as air pollution and genetics playing a minor role. 6 Acute exacerbation of COPD (AECOPD) is defined as an acute worsening of respiratory symptoms beyond baseline dyspnea, cough, and/or sputum production from normal day-to-day variation that necessitates a change in regular medication. 7, 8 AECOPD is a major indicator of disease severity and progression, which can be predictive of future exacerbations.
Alternatively, chronic bronchitis (CB) is defined clinically as chronic cough with sputum production for at least 3 months per year for 2 consecutive years. 9 COPD can present without CB, and CB can present without a diagnosis of COPD (CB symptoms without airway obstruction on pulmonary function tests). However, coexistence is still very common and the presence of one increases the risk for the other. CB is associated with an accelerated decline in lung function, a greater risk of acute exacerbations, worse respiratory symptoms, and possibly greater overall mortality. 10 Emphysema is defined pathologically as the presence of permanent enlargement of the airspaces distal to the terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis. 11 The aforementioned terms (COPD, CB, and emphysema) are used interchangeably in the literature to describe COPD; however, the distinction is very important to prevent confusion and to help provide accurate diagnosis and management.
SYMPTOMS
The most common presenting symptoms of COPD are productive cough and shortness of breath. Cough is often described by patients as a "smokers cough" usually associated with early morning sputum production. 12 The presence of productive cough for more than 3 months for 2 consecutive years fits the epidemiologic definition of CB, which fits under the broad category of COPD. If any of the aforementioned symptoms worsen, such as dyspnea, cough, or increasing amount or color of sputum, then a diagnosis of AECOPD is made. 13 
SIGNS
Signs of COPD include hyperinflation, barrel chest deformity, and wheezing. The presence of signs of respiratory distress such tachypnea, use of accessory muscles of res-piration, tachycardia, or cyanosis may indicate the presence of AECOPD. Bilateral lower limb edema, hepatic congestion, and ascites can develop because of cor pulmonale, which is pulmonary hypertension resulting from COPD. This is not an uncommon complication of untreated COPD as a result of pulmonary hypoxic vasoconstriction, especially if it is associated with untreated obstructive sleep apnea (overlap syndrome). 14 
DIAGNOSIS
According to 2015 GOLD criteria, the diagnosis of COPD is made by spirometry, using the forced expiratory volume in the first second (FEV 1 ) divided by the forced vital capacity (FVC). This ratio should be measured after bronchodilator use. The value of less than 0.70 (FEV 1 /FVC <0.70) is diagnostic of an obstructive process. 5 Staging is based on the post-bronchodilator FEV 1 .
The diagnosis of CB is made clinically on the basis of aforementioned criteria after exclusion of other causes of chronic productive cough, in contrast to emphysema, which is diagnosed radiographically or pathologically. AECOPD is diagnosed clinically on the basis of worsening of respiratory symptoms that is beyond day-to-day variation after exclusion of other conditions as clinically indicated.
Spirometry should be considered for any patient presenting with symptoms and signs in the presence of risk factors; however, routine screening is not recommended in the presence of risk factors without associated symptoms and should not be performed during an acute exacerbation. 5
RISK STRATIFICATION AND STAGING
According to 2015 GOLD guidelines, risk stratification and staging for patient with COPD depend on 3 main factors, which are as follows: On the basis of these 3 factors, patients with COPD can be categorized into one of the following categories (Figure): 1. Patient group A: Low risk, less symptoms 2. Patient group B: Low risk, more symptoms 3. Patient group C: High risk, less symptoms 4. Patient group D: High risk, more symptoms Generally speaking, patients with more than 2 prior exacerbations and/or a postbronchodilator FEV 1 that is less than 50% predicted are considered high-risk patients. These patients are thus group C (if mMRC = 0 or 1 or CAT <10) or group D (if mMRC ≥2 or CAT >10) (see the Figure) . Patients who do not meet either of the aforementioned criteria are generally considered low risk and can be categorized as group A or B according to their symptoms scores as well. 5
TREATMENT

General measures
Smoking cessation is strongly recommended for all active smokers. Pulmonary rehabilitation is indicated for patient with poor performance status and is discussed later. 15 All patients should receive the influenza vaccine. Pneumococcal vaccination should be given to all patients older than 65 years or to patients younger than 65 years with an FEV 1 of less than 40.
The beneficial effect of long-term oxygen therapy on survival in subjects with COPD and severe resting hypoxemia was demonstrated in 2 classic randomized, controlled clinical trials. These are the Nocturnal Oxygen Treatment Trial (NOTT) and the Medical Research Council (MRC) study. 16, 17 These trials demonstrated a higher mortality in a subset of patients who had lower oxygen levels. Specifically, the current accepted indication for home oxygen therapy is O 2 saturation less than 88 or PaO 2 less than 55 mm Hg-or O 2 saturation 88 to 89 or PaO 2 56 to 59 mm Hg if associated with pulmonary hypertension, polycythemia, or lower limb edema. It is strongly recommended to treat any associated sleep-related breathing disorder, which may further complicate the course of the disease.
Treatment of patients with stable COPD r Group A:
Patients have mild symptoms and are at low risk of exacerbation. Treatment mainly consists of as-needed bronchodilators for dyspnea with a β 2 -agonist or anticholinergic. r Group B: Patients have more symptoms but are still at low risk of exacerbation. Treatment includes a long-acting bronchodilator for symptomatic relieve (long-acting βagonist or long-acting anticholinergic). r Group C: Patients have mild symptoms but are at high risk for exacerbation. This group is treated with a combination of a longacting bronchodilator (either β-agonist or anticholinergic) and inhaled steroid. Alternatively, a combination of long-acting βagonist and long-acting anticholinergic may be used. The addition of PDE4 inhibitor (roflumilast) is indicated for patients with frequent exacerbations if they have the chronic bronchitic subtype and has been associated with a reduction in hospitalizations. r Group D: Patients have significant symptoms and are at high risk of exacerbation. Treatment with triple therapy is recommended (β-agonist, anticholinergic, and inhaled steroid); however, the evidence for this approach is weak. The addition of roflumilast is indicated for patients with the chronic bronchitic subtype.
Treatment of acute exacerbation
General measures
COPD exacerbations are associated with a significant increase in mortality, hospitalizations, and health care utilization. 7 Upon evaluating a patient presenting with possible COPD exacerbation, mimickers should be considered and treated appropriately if present. These include, but are not limited to, pulmonary edema, pneumonia, pneumothorax, pleural effusion, myocardial infarction, and pulmonary embolism. Failure to recognize mimickers will result in delay of therapy and subsequent worsening of outcome. Also, compliance with inhalers and the way they are self-administered should be assessed because interruption of maintenance therapy has also been shown to lead to exacerbations. 5
Disposition of patient
Almost 80% of patient with COPD exacerbation can be treated in an outpatient setting. 5 Hospitalization is indicated in certain conditions, which include the following 8 : r The presence of high-risk comorbid conditions, including pneumonia, cardiac arrhythmia, congestive heart failure, diabetes mellitus, and renal or liver failure; r Failure of outpatient management; r Marked increase in respiratory effort; r Inability to eat or sleep due to symptoms; r Worsening hypoxemia or hypercapnia; r Changes in mental status; and r Poor social support at home.
Indications for intensive care unit admission are primarily acute respiratory failure (hypoxia, hypercapnia) requiring invasive or noninvasive mechanical ventilation, presence of other end-organ dysfunction, that is, shock, renal, liver, or neurological disturbance, and/or hemodynamic instability. 8
Medications
r Bronchodilators form the cornerstone of therapy. This includes inhaled short-acting β-agonist, inhaled anticholinergic, or both. A systematic review of the route of delivery of short-acting bronchodilators found no significant differences in FEV 1 between metered-dose inhalers (with or without a spacer device) and nebulizers, although the latter can be more convenient for sicker patients 18 or those with very advanced COPD. r Steroids: Studies showed that steroids shorten recovery time and improve FEV 1 and oxygenation in COPD exacerbations. 19, 20 Hyperglycemia is the most frequent complication, and caution should be used in diabetic patients. 21 The dose utilized is controversial. A recently published trial (REDUCE trial) compared a 40-mg daily dose of prednisone for 5 days versus a 14-day course in an outpatient setting. This showed no significant difference in recurrence of exacerbations in the ensuing 6 months. Thus, a dose of 40 mg of prednisone per day for 5 days is reasonable in stable patients who can take oral medications. 22 Intravenous steroids should be implemented in patients who are not able to take oral medication. r Antibiotics: Antibiotic use in COPD exacerbation is controversial. A study in patients with COPD exacerbations requiring mechanical ventilation (invasive or noninvasive) demonstrated that no antibiotic was associated with increased mortality and a greater incidence of secondary nosocomial pneumonia. 23 The conclusion is that antibiotics are required in any patient requiring mechanical ventilation for COPD exacerbation. In addition, antibiotics should be given to patients who have 3 cardinal symptoms: (1) increase in dyspnea; (2) sputum volume; and (3) sputum purulence. Patients should also receive antibiotics if they have 2 of the cardinal symptoms, with one being increased purulence of sputum. 24, 25 Initial empiric treatment consists of either a macrolide, aminopenicillin with or without clavulanic acid, or doxycycline. Sputum culture is not routinely recommended in acute exacerbations. Exceptions are those patients with severe baseline airway obstruction, those with frequent exacerbations, and those requiring mechanical ventilation or have concomitant pneumonia. 26, 27 r Oxygenation and ventilation: Oxygen should be provided for a hypoxic patient, usually by nasal cannula, with an oxygen saturation goal of 88% to 92%. Higher oxygen levels are not recommended because these may blunt the hypoxic respiratory drive in hypercapnic patients. 28 r Ventilation can be provided noninvasively (NIV), that is, CPAP/BPAP, or invasively (endotracheal intubation). Use of NIV in AECOPD can reduce the need for endotracheal intubation, the length of hospital stay, and the in-hospital mortality rate. 29 Main indications for NIV are respiratory acidosis (arterial pH ≤7.35 and PaCO 2 >45 mm Hg) or severe dyspnea with clinical signs suggestive of respiratory muscle fatigue and increased work of breathing. 30, 31 The main contraindication for NIV is summarized in Table 2 . Indications to start mechanical ventilation are hemodynamic instability, altered level of consciousness, life-threatening arrhythmia, cardiorespiratory arrest, massive aspiration, or failure of NIV after 24 to 48 hours. 
Pulmonary rehabilitation
Pulmonary rehabilitation is an integral part of the clinical management and health maintenance of patients with COPD, especially those with poor functional status, who remain symptomatic or continue to have decreased function despite standard medical treatment. Pulmonary rehabilitation is recommended for patients with a diagnosis of COPD stage B-D and recommended within 6 weeks posthospitalization. The goals are to reduce symptoms, increase exercise tolerance, and increase muscle strength (peripheral and respiratory). 32 Exercise training causes several physiological adaptations to exercise, which can improve physical condition. Three basic types of exercises to be considered:
1. Aerobic exercise tends to improve the body's ability to use oxygen by decreasing the heart rate and blood pressure.
Strengthening or resistance exercises
can help build strength in the respiratory muscles.
Stretching and flexibility exercises such
as yoga and Pilates can enhance breathing coordination. In addition, pursed lip breathing can be used to increase oxygen level in the patient's body. Breathing games can be used to motivate patients to learn pursed lip breathing technique. Initial pulmonary rehabilitation therapy should be followed by lifelong maintenance.
SUMMARY
COPD is characterized by progressive airflow obstruction that is partially reversible, associated with inflammation in the airways, and systemic effects or comorbidities. The main cause is tobacco smoking, but other factors have been identified. AECOPD is a major indicator of disease severity and progression and can be predictive of future exacerbations. This may be prevented by smoking cessation, use of bronchodilators, and pneumococcal and influenza vaccination.
